Literature DB >> 8957739

Treatment of Cushing's disease by transsphenoidal, pituitary microsurgery: prognosis factors and long-term follow-up.

F Bakiri1, S Tatai, R Aouali, M Semrouni, P Derome, F Chitour, M Benmiloud.   

Abstract

Transsphenoidal pituitary microsurgery is considered as the best treatment of Cushing's disease. However, some recent studies reported disappointing results, leading their authors to suggest the possibility of returning to a first line adrenalectomy treatment. The aim of this study was to evaluate long-term results of transsphenoidal surgery in Cushing's disease, with special interest in factors that could affect the surgical outcome on the one hand and particular attention to surgical endocrine effects on the other. Fifty consecutive patients (34 females, 16 males, mean age 29.64 +/- 1.52 yr) were studied. The median post-operative follow-up was 71.5 months (range 25-219). Clinical, biological, surgical and pathological data between the success and failure groups were compared. Criteria of cure were: normal urinary free cortisol excretion, circadian cortisol rhythm and low dose dexamethasone test. Recovery of corticotroph and somatotroph functions were followed using the insulin test. Particular attention is given to clinical evolution in evaluating other pituitary functions. T4 or FT4, prolactin, E2 in women, testosterone in men, were measured. TRH and LHRH tests were not systematically performed. Only two parameters differed significantly between the cured and failure groups: the size of the adenomas was smaller and the pathological confirmation of the adenoma more frequent in the cured group. One patient had permanent corticotropic failure while two other had impaired response to hypoglycemia with normal cortisol basal levels. No acquired hypothyroidism nor hypogonadism were observed except in a patient who underwent two operations and radiotherapy. Recovery of GH function was slow. Definitive short stature was observed in all the patients whose disease began before the age of 16. Two patients had permanent diabetes insipidus. In conclusion, the most favorable prognosis in transsphenoidal surgery for Cushing's disease is observed in case of microadenoma confirmed by pathological examination. With this treatment, we obtained satisfactory results in Cushing's disease with minimal complications and no necessity of life-long endocrine substitutive therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957739     DOI: 10.1007/BF03349020

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  33 in total

Review 1.  The treatment of Cushing's syndrome.

Authors:  A B Atkinson
Journal:  Clin Endocrinol (Oxf)       Date:  1991-06       Impact factor: 3.478

2.  Therapy of Cushing disease: a consensus for pituitary microsurgery.

Authors:  J C Melby
Journal:  Ann Intern Med       Date:  1988-09-15       Impact factor: 25.391

3.  Restoration of dexamethasone suppression by incomplete adenomectomy in Cushing's disease.

Authors:  W J Jeffcoate; S Dauncey; C Selby
Journal:  Clin Endocrinol (Oxf)       Date:  1985-08       Impact factor: 3.478

4.  Transsphenoidal surgery for Cushing's disease: does what is removed determine the endocrine outcome?

Authors:  C W Burke; C B Adams; M M Esiri; C Morris; J S Bevan
Journal:  Clin Endocrinol (Oxf)       Date:  1990-10       Impact factor: 3.478

5.  Characterization of adrenal autonomy in Cushing's syndrome: a comparison between in vivo and in vitro responsiveness of the adrenal gland.

Authors:  S W Lamberts; J Zuiderwijk; P Uitterlinden; J J Blijd; H A Bruining; F H de Jong
Journal:  J Clin Endocrinol Metab       Date:  1990-01       Impact factor: 5.958

6.  Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing's disease before and after surgical cure.

Authors:  M A Magiakou; G Mastorakos; M T Gomez; S R Rose; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1994-01       Impact factor: 5.958

7.  Assessment of endocrine function after transsphenoidal surgery for Cushing's disease.

Authors:  D R McCance; D S Gordon; T F Fannin; D R Hadden; L Kennedy; B Sheridan; A B Atkinson
Journal:  Clin Endocrinol (Oxf)       Date:  1993-01       Impact factor: 3.478

8.  Endocrine function in patients with Cushing's disease before and after treatment.

Authors:  J Lindholm
Journal:  Clin Endocrinol (Oxf)       Date:  1992-02       Impact factor: 3.478

9.  Anterior pituitary function after transsphenoidal selective adenomectomy in patients with Cushing's disease.

Authors:  A Kuwayama; N Kageyama; T Nakane; M Watanabe; N Kanie
Journal:  J Clin Endocrinol Metab       Date:  1981-07       Impact factor: 5.958

10.  Occult ectopic secretion of corticotropin.

Authors:  J W Findling; J B Tyrrell
Journal:  Arch Intern Med       Date:  1986-05
View more
  5 in total

Review 1.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 2.  Management of Cushing disease.

Authors:  Nicholas A Tritos; Beverly M K Biller; Brooke Swearingen
Journal:  Nat Rev Endocrinol       Date:  2011-02-08       Impact factor: 43.330

Review 3.  Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

4.  Duration of post-operative hypocortisolism predicts sustained remission after pituitary surgery for Cushing's disease.

Authors:  Prachi Bansal; Anurag Lila; Manjunath Goroshi; Swati Jadhav; Nilesh Lomte; Kunal Thakkar; Atul Goel; Abhidha Shah; Shilpa Sankhe; Naina Goel; Neelam Jaguste; Tushar Bandgar; Nalini Shah
Journal:  Endocr Connect       Date:  2017-09-14       Impact factor: 3.335

5.  Endoscopic vs. microscopic transsphenoidal surgery for Cushing's disease: a systematic review and meta-analysis.

Authors:  Leonie H A Broersen; Nienke R Biermasz; Wouter R van Furth; Friso de Vries; Marco J T Verstegen; Olaf M Dekkers; Alberto M Pereira
Journal:  Pituitary       Date:  2018-10       Impact factor: 4.107

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.